China Indapamide Market
China Indapamide Market Size, Share & Trends Analysis By Product Type (Immediate-Release Tablets, Sustained/Extended-Release Tablets), By Strength (1.25 mg, 2.5 mg, Other Customized Dosages), By Application (Hypertension, Edema, Heart Failure), Forecast Period (2026-2035)
Industry Overview
China indapamide market was valued at $24.2 million in 2025 and is projected to reach $32.8 million by 2035, growing at a CAGR of 3.1% from 2026 to 2035. The China indapamide market is supported primarily by continued demand for pharmacological management of hypertension and the established use of indapamide as a thiazide-like diuretic. The market includes immediate-release and sustained-release formulations as well as fixed-dose combinations with other antihypertensive agents. Domestic manufacturers have expanded the availability of generic formulations, while established international pharmaceutical companies continue to maintain branded products and reference products in China. Sustained-release formulations are receiving greater attention because of their role in once-daily treatment and controlled drug exposure. Fixed-dose combinations are also becoming more relevant as hypertension management increasingly uses combination therapy. Regulatory approvals and consistency-evaluation requirements continue to shape competition among domestic manufacturers.
Market Dynamics
Growing Adoption of Sustained-Release Formulations
The China indapamide market is seeing continued use of sustained-release formulations in long-term hypertension management. These formulations provide controlled release of the active ingredient and support once-daily administration. Domestic manufacturers have expanded their presence in this product category alongside established international products. The availability of multiple sustained-release products is increasing competition among manufacturers. This trend is also linked with ongoing development of combination antihypertensive therapies containing indapamide. Regulatory approvals for such formulations are contributing to continued product availability in the Chinese market.
Expansion of Fixed-Dose Combination Therapies
Fixed-dose combinations containing indapamide are becoming an increasingly important product-development direction in China. Pharmaceutical companies are combining indapamide with other antihypertensive agents to address treatment requirements involving multiple mechanisms of blood-pressure control. This approach can provide patients with multiple active ingredients in a single dosage form. Recent regulatory activity involving indapamide-containing combinations demonstrates continued development in this area. Domestic manufacturers are participating alongside established multinational pharmaceutical companies. The trend is supporting broader application of indapamide beyond standalone antihypertensive formulations.
Market Segmentation
- Based on the product type, the market is segmented into immediate-release (IR) tablets and sustained/extended-release (SR/ER) tablets.
- Based on the strength, the market is segmented into 1.25 mg, 2.5 mg, and other customized dosages.
- Based on the application, the market is segmented into hypertension, edema, and heart failure.
Hypertension Segment to Lead the Market with the Largest Share
Hypertension remains the principal therapeutic application for indapamide in China because the drug is primarily used as an antihypertensive agent and is also incorporated into combination therapies. The product's role extends from conventional indapamide treatment to fixed-dose combinations designed for patients whose blood pressure is not adequately controlled with single-agent therapy. Recent Chinese product activity has particularly focused on combinations involving indapamide and renin-angiotensin-system therapies. The inclusion of indapamide-containing products in China's reimbursement and procurement environment supports continued availability through institutional and outpatient channels. This application therefore remains closely connected with long-term cardiovascular disease management and the broader need for sustained blood-pressure control.
Sustained-Release Tablets: A Key Segment in Market Growth
Sustained-release Tablets are an important subsegment of the China indapamide market because established domestic and international products are available in this formulation. Chinese procurement records identify manufacturers including Hefei Heyuan Pharmaceutical, Huangshan Zhonghuang Pharmaceutical, Jinan Gaohua Pharmaceutical, Zhen'ao Jinyinhua Pharmaceutical, and Ningxia Kangya Pharmaceutical. The formulation is also used as the indapamide component in newer fixed-dose antihypertensive products. Continued regulatory activity around these products indicates an established manufacturing base and ongoing competition among generic suppliers.
Market Players Outlook
The major companies operating in the China indapamide market include Les Laboratoires Servier, Shenzhen Salubris Pharmaceuticals Co., Ltd., Tianjin Lisheng Pharmaceutical Co., Ltd., China National Pharmaceutical Group Corporation, and Hefei Heyuan Pharmaceutical Co., Ltd., among others. Market players are leveraging partnerships, collaborations, mergers and acquisition strategies for business expansion and innovative product development to maintain their market positioning.
Recent Development
- In 2025, Salubris launched Fulian® (Allisartan Isoproxil and Indapamide Sustained-release Tablets) in China. The company's official development history identifies Fulian® as China's first ARB plus thiazide-diuretic compound sustained-release antihypertensive new drug and records its launch in 2025.
The Report Covers
- Market value data analysis for 2025 and forecast to 2035.
- Annualized market revenues ($ million) for each market segment.
- Key companies operating in the China indapamide market. Based on the availability of data, information related to new products, and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market-entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
- Report Summary
- Current Industry Analysis and Growth Potential Outlook
- China Indapamide Market Sales Analysis – Product Type | Strength | Application ($ Million)
- Indapamide Market Sales Performance of Top Countries
- Research Methodology
- Primary Research Approach
- Secondary Research Approach
- Market Snapshot
- Market Overview and Insights
- Scope of the Study
- Analyst Insight & Current Market Trends
- Key Indapamide Industry Trends
- Market Recommendations
- Porter's Five Forces Analysis for the Indapamide Market
- Competitive Rivalry
- Threat of New Entrants
- Bargaining Power of Suppliers
- Bargaining Power of Buyers
- Threat of Substitutes
- Market Determinants
- Market Drivers
- Drivers For China Indapamide Market: Impact Analysis
- Market Pain Points and Challenges
- Restraints For China Indapamide Market: Impact Analysis
- Market Opportunities
- Opportunities For China Indapamide Market: Impact Analysis
- Market Drivers
- Competitive Landscape
- Competitive Dashboard – Indapamide Market Revenue and Share by Manufacturers
- Indapamide Product Comparison Analysis
- Top Market Player Ranking Matrix
- Key Company Analysis
- China National Pharmaceutical Group Corporation
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Hefei Heyuan Pharmaceutical Co., Ltd.
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Les Laboratoires Servier
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Shenzhen Salubris Pharmaceuticals Co., Ltd.
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Tianjin Lisheng Pharmaceutical Co., Ltd.
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Top Winning Strategies by Market Players
- Merger and Acquisition
- Product Launch
- Partnership And Collaboration
- China National Pharmaceutical Group Corporation
- Key Company Analysis
- China Indapamide Market Sales Analysis by Product Type ($ Million)
- Immediate-Release (IR) Tablets
- Sustained/Extended-Release (SR/ER) Tablets
- China Indapamide Market Sales Analysis by Strength ($ Million)
- 25 mg
- 5 mg
- Other Customized Dosages
- China Indapamide Market Sales Analysis by Application ($ Million)
- Hypertension
- Edema (Fluid Retention)
- Heart Failure (Adjunct Therapy)
- Company Profiles
- Beijing Shiyanjing Pharmaceutical Co., Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- China National Pharmaceutical Group Corporation
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Chongqing Yaoyou Pharmaceutical Co., Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Haisco Pharmaceutical Group Co., Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Hefei Heyuan Pharmaceutical Co., Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Huangshan Zhonghuang Pharmaceutical Co., Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Hubei Huirui Pharmaceutical Co., Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Hubei Shubang Pharmaceutical Co., Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Jiangxi Shimei Pharmaceutical Co., Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Jinan Gaohua Pharmaceutical Co., Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Les Laboratoires Servier
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Nanchang Feihong Pharmaceutical Co., Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Ningxia Kangya Pharmaceutical Co., Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Puyang Huiyuan Pharmaceutical Co., Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Shandong Fangming Pharmaceutical Group Co., Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Shandong Luyin Pharmaceutical Co., Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Suicheng Pharmaceutical Co., Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Suzhou Lixin Pharmaceutical Co., Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Tianjin Lisheng Pharmaceutical Co., Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Tianjin Pacific Chemical and Pharmaceutical Co., Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Tianjin Shijinjin Pharmaceutical Co., Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Tipr Pharmaceutical Co., Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Wuhan Wuyao Pharmaceutical Co., Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Zhejiang Apeloa Kangyu Pharmaceutical Co., Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Zhen'ao Jinyinhua Pharmaceutical Co., Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Beijing Shiyanjing Pharmaceutical Co., Ltd.
1. China Indapamide Market Research and Analysis by Product Type, 2025–2035 ($ Million)
2. China Immediate-Release (IR) Tablets Indapamide Market Research and Analysis by Region, 2025–2035 ($ Million)
3. China Sustained/Extended-Release (SR/ER) Tablets Indapamide Market Research and Analysis by Region, 2025–2035 ($ Million)
4. China Indapamide Market Research and Analysis by Strength, 2025–2035 ($ Million)
5. China 1.25 mg Indapamide Market Research and Analysis by Region, 2025–2035 ($ Million)
6. China 2.5 mg Indapamide Market Research and Analysis by Region, 2025–2035 ($ Million)
7. China Other Customized Dosages Indapamide Market Research and Analysis by Region, 2025–2035 ($ Million)
8. China Indapamide Market Research and Analysis by Application, 2025–2035 ($ Million)
9. China Indapamide for Hypertension Research and Analysis by Region, 2025–2035 ($ Million)
10. China Indapamide for Edema (Fluid Retention) Research and Analysis by Region, 2025–2035 ($ Million)
11. China Indapamide for Heart Failure (Adjunct Therapy) Research and Analysis by Region, 2025–2035 ($ Million)
1. China Indapamide Market Share by Product Type, 2025 vs 2035 (%)
2. China Immediate-Release (IR) Tablets Indapamide Market Research and Analysis by Region, 2025 Vs 2035 (%)
3. China Sustained/Extended-Release (SR/ER) Tablets Indapamide Market Research and Analysis by Region, 2025 Vs 2035 (%)
4. China Indapamide Market Share by Strength, 2025 vs 2035 (%)
5. China 1.25 mg Indapamide Market Research and Analysis by Region, 2025 Vs 2035 (%)
6. China 2.5 mg Indapamide Market Research and Analysis by Region, 2025 vs 2035 (%)
7. China Other Customized Dosages Indapamide Market Research and Analysis by Region, 2025 Vs 2035 (%)
8. China Indapamide Market Share by Application, 2025 vs 2035 (%)
9. China Indapamide for Hypertension Market Research and Analysis by Region, 2025 vs 2035 (%)
10. China Indapamide for Edema (Fluid Retention) Market Research and Analysis by Region, 2025 Vs 2035 (%)
11. China Indapamide for Heart Failure (Adjunct Therapy) Market Research and Analysis by Region, 2025 Vs 2035 (%)
- Printable version
- No restriction to number of users within the company
